What TransCure bioServices does

TransCure bioServices SAS is a France-based preclinical Contract Research Organization founded in 2012 and headquartered in Archamps (registered at the Registry of Thonon-les-Bains). The company specializes in humanized mouse models for translational drug development, offering four core model classes: CD34+ humanized immune system mice, humanized liver mice, double humanized mice combining both systems, and conventional immunodeficient/immunocompetent mice. These models are applied across a portfolio of disease models spanning oncology (human CDX, human PDX, syngeneic), inflammatory disease (IBD, MASH, GvHD, lung inflammation), and infectious disease (HIV, HBV), complemented by hepatotoxicity and immunotoxicity screening services.

The underlying technology platform combines wet-lab biology with an instrumentation stack including three Thermo Fisher Attune NxT flow cytometers, a BD FACS Melody cell sorter, an Aperio Versa digital pathology scanner, a Vilber Newton bioluminescence imaging system, and primary cell culture assays for in vitro mechanism-of-action work. Study operations are supported by RADAR, a custom in-house tracking software for traceability and reproducibility. The company holds AAALAC International accreditation (since 2022), is a GIRCOR charter signatory, and operates a GLP-aligned quality system.

The business model is project-based B2B preclinical CRO services sold through a consultative, sales-led motion targeting biotech and pharmaceutical enterprise clients, with services covering advanced therapeutic modalities including bi-specific antibodies, CAR-T, and antibody-drug conjugates. All 70 collaborators are based in France, and the operating geography has historically been Europe-focused. On January 20, 2026, Taconic Biosciences announced its acquisition of TransCure bioServices, establishing a fully integrated translational research platform that combines Taconic's global rodent model production infrastructure with TransCure's disease-specific translational pharmacology, flow cytometry, and in vivo capabilities.

Name

TransCure bioServices

Legal name

TransCure BioServices SAS

Website

https://transcurebioservices.com

Company type

Private

Founded year

2012

Operating status

Acquired

Headcount range

1–10 employees

Short description

TransCure bioServices is a France-based preclinical CRO founded in 2012 that provides humanized mouse models and translational pharmacology services to biotech and pharmaceutical clients developing advanced therapeutics, including antibodies, CAR-T, and ADCs.

Ownership category

akta.pro rank

Product category

Preclinical CRO Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Humanized mouse models
• Preclinical CRO services
• Translational pharmacology
• Immunotoxicity assessment
• Oncology disease models

Headquarters

HQ city

Carouge

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Preclinical CRO Services: Contract research organization providing preclinical studies using humanized mouse models for biotech and pharmaceutical companies. Services include translational pharmacology, flow cytometry, and advanced in vivo study capabilities. Revenue generated through project-based contracts for specific preclinical studies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

TransCure bioServices is a preclinical contract research organization that designs and executes in vivo pharmacology studies using proprietary humanized and conventional mouse models. It delivers customized preclinical packages — including model selection, study execution, and readouts such as flow cytometry, immunohistochemistry, and in vivo imaging — for biotech, pharmaceutical, and academic sponsors advancing novel therapeutics.

Product overview

TransCure bioServices is a preclinical Contract Research Organization (CRO) offering a portfolio of humanized and conventional mouse models for translational research. The core product line includes four distinct mouse model types: CD34+ Humanized Mouse, Humanized Liver Mouse Model, Double Humanized Mouse Model, and Conventional Mouse Models. These models are applied across multiple disease model categories—Oncology (Human CDX, Human PDX, Syngeneic), Inflammatory diseases (IBD, MASH, GvHD, Lung Inflammation), and Infectious diseases (HIV, HBV). The company also provides dedicated toxicity assessment services (Hepatotoxicity, Immunotoxicity) and general preclinical CRO services. The offering is a services-based portfolio rather than a unified software platform, with models validated over 12 years of experience, now integrated with Taconic Biosciences following acquisition.

Differentiator

Problem solved

Functional benefit

Products and services

• CD34+ Humanized Mouse Model Humanized mouse model engrafted with human CD34+ hematopoietic stem cells, supplied for and used within preclinical efficacy, immunotoxicity, and mechanism-of-action studies for biotech, pharma, and academic sponsors.
• Humanized Liver Mouse Model Mouse model harboring humanized liver tissue for preclinical studies of hepatic pharmacology, metabolism, hepatotoxicity, and HBV-related research.
• Double Humanized Mouse Model Mouse model reconstituted with both human hematopoietic cells and human liver tissue, enabling combined immune and hepatic preclinical readouts in a single platform.
• Conventional Mouse Models Conventional (non-humanized) mouse models used as comparators and as standalone platforms for syngeneic tumor studies, pharmacology baselines, and routine preclinical in vivo work.
• Oncology Disease Models (CDX, PDX, Syngeneic) Preclinical oncology service line providing human cell-line-derived xenograft (CDX), patient-derived xenograft (PDX), and syngeneic tumor mouse models for efficacy, combination, and mechanism studies in oncology drug development.
• Immunology and Inflammation Disease Models (IBD, MASH, GvHD, Lung Inflammation) Preclinical immunology disease model services for inflammatory bowel disease (IBD), MASH, graft-versus-host disease (GvHD), and lung inflammation, supporting efficacy and pharmacodynamic studies of immuno-modulating therapeutics.
• Infectious Disease Models (HIV, HBV) Preclinical HIV and HBV infectious disease studies executed on humanized mouse platforms, supporting antiviral efficacy, mechanism, and immunogenicity readouts for biotech and academic sponsors.
• Hepatotoxicity Assessment Service Preclinical hepatotoxicity assessment service leveraging humanized liver mouse models to evaluate drug-induced liver injury, hepatic enzyme changes, and histopathology for candidate therapeutics.
• Immunotoxicity Assessment Service Preclinical immunotoxicity assessment service combining humanized mouse studies with flow cytometry and immunohistochemistry readouts to characterize immune-mediated effects of drug candidates.
• RADAR Study Tracking Platform Proprietary RADAR software platform providing clients with real-time visibility into preclinical study progress, milestones, and deliverables across TransCure bioServices' humanized mouse model programs.

Quantifiable outcome

• Humanized mice engraftment with complete human immune system reconstitution including mature T cells, NK cells, and macrophages
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Taconic BiosciencescoreStrategic or Co-development Partner · 20 January 2026Taconic Biosciences, a global leader in genetically engineered rodent models, acquired TransCure bioServices SAS in January 2026. The acquisition establishes a fully integrated translational research platform, combining Taconic's global production infrastructure and validated models with TransCure's expertise in disease-specific translational pharmacology, flow cytometry, and advanced in vivo study capabilities. The combined entity supports advanced therapeutic modalities including bi-specific antibodies, CAR-T therapies, and antibody-drug conjugates.

Scale indicators4 records

Recent moves4 records

Expansion highlights6 records

Direct peers

• Taconic Biosciences: Parent company and most direct comparable: a global leader in genetically engineered rodent models and humanized mouse generation. Since the January 2026 acquisition, Taconic and TransCure operate as a combined translational research platform, making the two directly aligned in business model, customer base, and core technology.
• Crown Bioscience: A preclinical CRO specializing in oncology and immuno-oncology translational research, including humanized mouse models, PDX, and CDX platforms. Directly comparable to TransCure on offering (humanized mice for oncology/inflammation/IBD), customer base (biotech sponsors), and study-based CRO business model.
• genOway: A French/European specialist in custom genetically engineered mouse models, including humanized models. Directly comparable on technology (custom mouse model generation) and the European customer base, with stronger custom-model design services rather than full CRO study delivery.

Broad incumbents

• The Jackson Laboratory: A major nonprofit biomedical research institute and one of the largest providers of genetically defined and humanized mouse models worldwide. Overlaps with TransCure on mouse model provision and preclinical services but operates at significantly greater scale and with broader model portfolios.
• Charles River Laboratories: One of the world's largest preclinical CROs, offering a broad menu of rodent research models, discovery, and safety assessment services. Competes with TransCure in humanized mouse and preclinical study services but as part of a much larger full-service preclinical portfolio.
• Inotiv: A preclinical CRO and research-models provider (formed via Envigo-Harlan consolidation) offering animal models, discovery, and safety assessment services. Competes with TransCure across both model provision and contract research, but at much greater scale.
• WuXi AppTec (WuXi Biology): Global CRO/CDMO with preclinical biology capabilities, including humanized mouse model-based efficacy and safety studies. Highly relevant comparable on CRO business model and customer segments, though much larger and more diversified.

Emerging players

• Cyagen Biosciences: A China-based provider of custom mouse models, including humanized immune system models, with growing preclinical services capability. Directly comparable on humanized mouse technology and biotech customer base; smaller global footprint than the major incumbents.
• Biocytogen: Preclinical CRO offering humanized mouse models, antibody discovery, and in vivo pharmacology services. Comparable in services (humanized mice for immuno-oncology and inflammation) and customer base, with a stronger emphasis on antibody discovery.
• Reaction Biology: A preclinical CRO offering in vivo and in vitro pharmacology services with focus on oncology and immunology. Comparable on CRO study services and biotech sponsor customer base, with relatively smaller footprint than the largest incumbents.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/transcure-bioservices
• Xx.com/_TransCure

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TransCure bioServices